Valeant Pharmaceuticals Intl Company Profile (TSE:VRX)

About Valeant Pharmaceuticals Intl (TSE:VRX)

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: TSE:VRX
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: C$6.38 billion
  • Outstanding Shares: 347,906,000
Average Prices:
  • 50 Day Moving Avg: C$14.30
  • 200 Day Moving Avg: C$18.40
  • 52 Week Range: C$11.20 - C$42.25
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: -0.41
Sales & Book Value:
  • Annual Revenue: C$9.41 billion
  • Price / Sales: 0.68
  • Book Value: C$11.19 per share
  • Price / Book: 1.64
Profitability:
  • EBIDTA: C$3.9 billion
Misc:
  • Average Volume: 1.48 million shs.
  • Short Ratio: 7.38
 

Frequently Asked Questions for Valeant Pharmaceuticals Intl (TSE:VRX)

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the Tornton Stock Exchange (TSX) under the ticker symbol "VRX."

Where is Valeant Pharmaceuticals Intl's stock going? Where will Valeant Pharmaceuticals Intl's stock price be in 2017?

4 brokerages have issued 12 month price objectives for Valeant Pharmaceuticals Intl's shares. Their forecasts range from C$19.00 to C$26.00. On average, they anticipate Valeant Pharmaceuticals Intl's stock price to reach C$21.83 in the next year. View Analyst Ratings for Valeant Pharmaceuticals Intl.

Who are some of Valeant Pharmaceuticals Intl's key competitors?

How do I buy Valeant Pharmaceuticals Intl stock?

Shares of Valeant Pharmaceuticals Intl and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How much does a share of Valeant Pharmaceuticals Intl stock cost?

One share of Valeant Pharmaceuticals Intl stock can currently be purchased for approximately C$18.34.

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals Intl (TSE:VRX) (?)
Ratings Breakdown: 4 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: C$21.83

Analysts' Ratings History for Valeant Pharmaceuticals Intl (TSE:VRX)
Show:
DateFirmActionRatingPrice TargetDetails
5/10/2017TD SecuritiesLower Price TargetHoldC$20.50View Rating Details
5/10/2017ScotiabankBoost Price TargetSector PerformC$19.00View Rating Details
5/10/2017Royal Bank of CanadaBoost Price TargetSector PerformC$26.00View Rating Details
12/15/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details
11/19/2015Citigroup IncReiterated RatingOverweightView Rating Details
11/2/2015Goldman Sachs Group IncDowngradeBuy -> NeutralView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Valeant Pharmaceuticals Intl (TSE:VRX)
Earnings by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)
Earnings History by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2014$1.83$1.90$2.05 billionViewN/AView Earnings Details
8/7/20132Q13$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Valeant Pharmaceuticals Intl (TSE:VRX)
Current Year EPS Consensus Estimate: $3.61 EPS

Dividends

Dividend History for Valeant Pharmaceuticals Intl (TSE:VRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Valeant Pharmaceuticals Intl (TSE:VRX)
Insider Trades by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)
Insider Trades by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2017Schutter Richard Urbain DeDirectorBuy20,000C$13.90C$278,000.00
3/15/2017Schutter Richard Urbain DeDirectorBuy10,000C$10.80C$108,000.00
11/5/2015J. Michael PearsonDirectorSell350,000C$0.00C$0.00
10/21/2015Ron FarmerDirectorBuy1,000C$193.00C$193,000.00
5/26/2015Whitaker AnneInsiderBuy2,500C$234.00C$585,000.00
5/4/2015Robert Roswell Chai-OnnInsiderSell90,938C$222.54C$20,237,433.46
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Valeant Pharmaceuticals Intl (TSE:VRX)
Latest Headlines for Valeant Pharmaceuticals Intl (TSE:VRX)
Source:
DateHeadline
finance.yahoo.com logoWife of Soundgarden's Cornell calls suicide 'inexplicable'
finance.yahoo.com - May 19 at 1:39 PM
prnewswire.com logoStatement Regarding Xifaxan Intellectual Property Litigation - PR Newswire (press release)
www.prnewswire.com - May 17 at 10:12 PM
nasdaq.com logoJeff Ubben Buys Bioverativ Inc, Valeant Pharmaceuticals International Inc, NetScout Systems ...
www.nasdaq.com - May 16 at 11:43 PM
americanbankingnews.com logoValeant Pharmaceuticals Intl Inc (VRX) Director Acquires C$278,000.00 in Stock
www.americanbankingnews.com - May 16 at 7:56 AM
seekingalpha.com logo5 More Reasons Valeant Pharmaceuticals Bottomed
seekingalpha.com - May 15 at 7:44 PM
finance.yahoo.com logoEdited Transcript of VRX.TO earnings conference call or presentation 9-May-17 12:00pm GMT
finance.yahoo.com - May 12 at 4:14 AM
finance.yahoo.com logoValeant Pharmaceuticals: Feeling Sentimental?
finance.yahoo.com - May 12 at 4:14 AM
finance.yahoo.com logoValeant Pharmaceuticals International, Inc. – Value Analysis (TORONTO:VRX) : May 11, 2017
finance.yahoo.com - May 12 at 4:14 AM
seekingalpha.com logoValeant's Story Is Changing - Seeking Alpha
seekingalpha.com - May 11 at 3:18 AM
seekingalpha.com logoValeant: The Market Has Spoken - Seeking Alpha
seekingalpha.com - May 11 at 3:18 AM
investorplace.com logoWednesday's Vital Data: Nvidia Corporation (NVDA), Walt Disney Co (DIS) and Valeant Pharmaceuticals Intl Inc (VRX) - Investorplace.com
investorplace.com - May 11 at 3:18 AM
finance.yahoo.com logoValeant Rockets Higher: Why I'm Not Buying
finance.yahoo.com - May 11 at 3:18 AM
americanbankingnews.com logoScotiabank Boosts Valeant Pharmaceuticals Intl Inc (VRX) Price Target to C$19.00
www.americanbankingnews.com - May 10 at 4:38 PM
americanbankingnews.com logoValeant Pharmaceuticals Intl Inc (VRX) Price Target Lowered to C$20.50 at TD Securities
www.americanbankingnews.com - May 10 at 4:38 PM
americanbankingnews.com logoValeant Pharmaceuticals Intl Inc (VRX) Price Target Increased to C$26.00 by Analysts at Royal Bank of Canada
www.americanbankingnews.com - May 10 at 11:40 AM
marketwatch.com logoValeant shares rocket 24% as investors cheer moves to reduce debt
www.marketwatch.com - May 9 at 8:03 PM
seekingalpha.com logoValeant Pharmaceuticals International (VRX) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:03 PM
finance.yahoo.com logoS&P 500 Turns Down
finance.yahoo.com - May 9 at 8:03 PM
finance.yahoo.com logoStocks Lifted by Upbeat Earnings, Stable Commodity Prices
finance.yahoo.com - May 9 at 9:42 AM
marketbeat.com logoDrugmaker Valeant tops 1Q profit forecasts, chops debt again
marketbeat.com - May 9 at 8:43 AM
marketbeat.com logoValeant tops 1Q profit forecasts
marketbeat.com - May 9 at 7:49 AM
finance.yahoo.com logoBausch + Lomb Announces PDUFA Date For New OTC Redness Reliever, Brimonidine Tartrate Ophthalmic Solution, 0.025%
finance.yahoo.com - May 8 at 8:06 PM
seekingalpha.com logoValeant: Disappointing Earnings? - Seeking Alpha
seekingalpha.com - May 7 at 10:28 PM
americanbankingnews.com logoValeant Pharmaceuticals Intl Inc (VRX) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:28 AM
seekingalpha.com logoValeant: Still A Bad Investment - Seeking Alpha
seekingalpha.com - May 5 at 3:26 AM
nasdaq.com logoVRX June 23rd Options Begin Trading - Nasdaq
www.nasdaq.com - May 5 at 3:26 AM
seekingalpha.com logoName Change: Signal Decoded - Seeking Alpha
seekingalpha.com - May 5 at 3:26 AM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Could More Than Double - Investorplace.com
investorplace.com - May 5 at 3:26 AM
finance.yahoo.com logoShocker: Valeant Pharmaceuticals Slides Another 16% in April. Here's the Big Reason Why
finance.yahoo.com - May 5 at 3:26 AM
finance.yahoo.com logoValeant: When Earnings are Almost an Afterthought
finance.yahoo.com - May 5 at 3:26 AM
seekingalpha.com logoBuy Valeant Before Earnings? - Seeking Alpha
seekingalpha.com - May 2 at 8:22 AM
finance.yahoo.com logo[$$] Valeant Pays Down $220 Million in Unscheduled Debt Payments
finance.yahoo.com - May 2 at 8:22 AM
streetinsider.com logoValeant Pharma (VRX) Reduces Debt by Another ~$220M
www.streetinsider.com - May 1 at 10:18 AM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Still Looks Toxic - Investorplace.com
investorplace.com - April 28 at 10:33 AM
americanbankingnews.com logoScotiabank Trims Valeant Pharmaceuticals Intl Inc (VRX) Target Price to C$16.00
www.americanbankingnews.com - April 26 at 8:24 PM
finance.yahoo.com logoWill Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?
finance.yahoo.com - April 25 at 8:45 AM
seekingalpha.com logoValeant Is Unfairly Undervalued II - Valeant Pharmaceuticals ... - Seeking Alpha
seekingalpha.com - April 24 at 6:56 PM
finance.yahoo.com logoResearch Reports Initiated on Healthcare Stocks: Valeant Pharma, Knight Therapeutics, Merus Labs International, and Nuvo Pharma
finance.yahoo.com - April 24 at 9:09 AM
finance.yahoo.com logoValeant: Will Earnings Even Matter?
finance.yahoo.com - April 21 at 12:51 AM
finance.yahoo.com logoHow Drug-Company 'Benevolence' Silences the Sick
finance.yahoo.com - April 18 at 7:41 PM
americanbankingnews.com logoValeant Pharmaceuticals Intl Inc (VRX) Given "Outperform" Rating at Royal Bank of Canada
www.americanbankingnews.com - April 18 at 3:04 PM
finance.yahoo.com logoValeant Pharmaceuticals' Market Cap Is Now Lower Than Its Projected Full-Year EBITDA
finance.yahoo.com - April 13 at 11:17 PM
finance.yahoo.com logoValeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call
finance.yahoo.com - April 10 at 8:04 PM
finance.yahoo.com logoValeant Shares on Pace to Finish Week at Lowest Level Since 2008
finance.yahoo.com - April 7 at 1:26 PM
americanbankingnews.com logoValeant Pharmaceuticals Intl Inc (VRX) Earns Sector Perform Rating from Royal Bank of Canada
www.americanbankingnews.com - April 3 at 3:46 PM
americanbankingnews.com logoValeant Pharmaceuticals Intl Inc (VRX) Rating Reiterated by Royal Bank of Canada
www.americanbankingnews.com - March 31 at 7:48 AM
zacks.com logoWhat Makes Valeant Pharmaceuticals (VRX) a Strong Sell?
www.zacks.com - March 30 at 8:17 AM
bloomberg.com logoAckman Is ‘Profoundly’ Sorry for $4 Billion Valeant ‘Mistake’
www.bloomberg.com - March 30 at 8:17 AM
blogs.barrons.com logoShares of Valeant Rise as 2018 Debt Maturities Extended
blogs.barrons.com - March 30 at 8:17 AM
thestreet.com logoValeant's Banks Extend a Lifeline
www.thestreet.com - March 30 at 8:17 AM

Social

Valeant Pharmaceuticals Intl (VRX) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff